Rheumatoid Arthritis accounts for 18.9% share of global Immunology clinical trial activity in 2020

Rheumatoid Arthritis accounted for an 18.9% share of the global clinical trials within the Immunology therapy area in 2020, registering a decrease of 4.4% when compared with the last ten-year average of 23.3% share, according to GlobalData.

Industry sponsored trials outnumber non-industry sponsored trials for Rheumatoid Arthritis

Industry sponsored trials held a 61.1% share of all the clinical trials for Rheumatoid Arthritis indication in 2020, registering an increase of 2.7% when compared with the ten-year average of 58.4%. Non-industry sponsored trials accounted for a 38.9% share in 2020, marking a decrease of 2.7% over the ten-year average of 41.6%

Top regions of industry sponsored Rheumatoid Arthritis trials

Asia-Pacific was the top region for industry sponsored Rheumatoid Arthritis trials, accounting for a 62.1% share in 2020, when compared with the five-year average of 58.2% and ten-year average of 49.0%.

Europe was at the second position with a 28.4% share in 2020, over the five-year average of 36.4% and ten-year average of 44.9%, followed by North America with a 20.0% share in 2020, as against five-year and ten-year averages of 26.2% and 32.5% respectively.

South and Central America stood fourth with a 5.3% share in 2020, compared with the five-year average of 9.5% and ten-year average of 13.0%, followed by Middle East and Africa with a 3.2% share in 2020, over five-year and ten-year averages of 7.9% and 10.4% respectively.

China was the top country for industry sponsored Rheumatoid Arthritis trials, accounting for a 47.4% share in 2020, as against the five-year average of 26.1% and ten-year average of 15.3%.

The US held a 17.9% share in 2020, over the five-year average of 22.5% and ten-year average of 28.9%, followed by Germany with an 11.6% share in 2020, compared with the five-year and ten-year averages of 15.8% and 16.3% respectively.

Poland held an 8.4% share in 2020, as against the five-year average of 15.5% and ten-year average of 16.6%.

Bulgaria held a 7.4% share in 2020, over the five-year and ten-year averages of 10.0% and 9.8% respectively.

Top regions of non-industry sponsored Rheumatoid Arthritis trials

Asia-Pacific was the top region for non-industry sponsored Rheumatoid Arthritis trials, accounting for a 47.5% share in 2020 when compared with the five-year average of 55.7% and ten-year average of 52.2%.

Europe was at the second position with a 35.6% share in 2020, over the five-year and ten-year averages of 23.4% and 27.3% respectively, followed by Middle East and Africa with a 10.2% share in 2020, as against the five-year average of 11.5% and ten-year average of 9.8%.

North America stood at the fourth position with a 5.1% share in 2020, compared with the five-year average of 9.7% and ten-year average of 10.8%, followed by South and Central America with a 1.7% share in 2020, over the five-year and ten-year averages of 1.8% and 1.8% respectively.

China was the top country for non-industry sponsored Rheumatoid Arthritis trials, accounting for a 20.3% share in 2020, as against the five-year average of 17.1% and ten-year average of 12.7%.

The Netherlands held a 13.6% share in 2020, over the five-year average of 3.8% and ten-year average of 5.3%, followed by Japan with a 10.2% share, compared with the five-year and ten-year averages of 18.0% and 25.4% respectively.

India held an 8.5% share in 2020, as against the five-year average of 15.1% and ten-year average of 9.7%.

France held a 6.8% share in 2020, over the five-year average of 3.6% and ten-year average of 4.2%.

Phase I trials lead industry sponsored clinical trials for Rheumatoid Arthritis in 2020

Phase I trials held a 65.7% share of industry sponsored clinical trials for Rheumatoid Arthritis in 2020, over the five-year average of 50.5% and ten-year average of 43.4%.

Phase IV trials held a 12.1% share in 2020, as against the five-year average of 15.3% and ten-year average of 19.3%. Phase II trials held an 11.1% share in 2020, compared with the five-year and ten-year averages of 16.7% and 18.6% respectively.

Phase III trials held an 11.1% share in 2020, over the five-year average of 17.4% and ten-year average of 18.8%.

Phase IV trials lead non-industry sponsored clinical trials for Rheumatoid Arthritis in 2020

Phase IV trials held a 46.0% share of non-industry sponsored clinical trials for Rheumatoid Arthritis in 2020, over the five-year average of 34.1% and ten-year average of 37.5%.

Phase II trials held a 31.7% share in 2020, as against the five-year average of 46.5% and ten-year average of 46.0%. Phase III trials held an 11.1% share, compared with the five-year and ten-year averages of 12.9% and 11.9% respectively.

Phase I trials held a 11.1% share in 2020, over the five-year average of 6.4% and ten-year average of 4.7%.

Methodology:

The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.